Haifa Hamdi, PhD
About Haifa Hamdi, PhD
Haifa Hamdi, PhD, is the founder of Ibioc Translational & Development and currently works with AlloVir for analytical development. She has extensive experience in immunology and cell therapy, having held various research and leadership positions in notable institutions and companies across the United States and Europe.
Current Role at AlloVir
Haifa Hamdi, PhD, currently serves as the Founder of Ibioc Translational & Development and has a contract with AlloVir for analytical development. She has been in this role since 2022. Her work focuses on advancing analytical methodologies within the context of AlloVir's projects.
Previous Experience at MD Anderson Cancer Center
Haifa Hamdi worked as a Research Scientist at MD Anderson Cancer Center from 2016 to 2018. During her tenure, she contributed to various research initiatives in the field of cancer treatment and immunology, enhancing her expertise in translational research.
Educational Background
Haifa Hamdi obtained her Doctor of Philosophy (Ph.D.) from the University Paris XI, where she studied from 2002 to 2006. She also holds a Master's degree from Université de Technologie de Compiègne, completed in 2002, and a Bachelor's degree from Université Joseph Fourier (Grenoble I), achieved in 2001.
Experience in Immunology and Cell Therapy
Haifa Hamdi has extensive experience in immunology and cell therapy. She served as a Senior Scientist at Bellicum Pharmaceuticals, Inc. from 2018 to 2020, focusing on assay validation. Additionally, she was the Head of Analytical Development & QC at Kiromic Biopharma, Inc. from 2021 to 2022, overseeing allogeneic cell therapy projects.
Postdoctoral Research Experience
Haifa Hamdi has held several postdoctoral research positions. She worked as a Postdoctoral Researcher at Inserm from 2010 to 2012 and at Université libre de Bruxelles from 2007 to 2009. These roles contributed to her development as a researcher in the fields of immunology and translational medicine.